Physician

Amr Z Hegazi, MD

According to 2025 Medicare claims, Amr Hegazi, MD (NPI: 1366443152) practices hematology/oncology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Frederick, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21702-4501.

Hegazi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,143 traditional Medicare patients, billed 280,813 HCPCS/CPT codes, and received $5,127,179 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,175 prescription claims across 217 beneficiaries totaling $3,129,358 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 45 claims. Open Payments data shows 45 records totaling $1,109. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,963,895 to $5,127,179. Similarly, Part D prescription costs have moved sharply higher in recent years, from $778,526 to $3,129,358. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,542 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	526	246,552	$1,963,895
2016	655	268,171	$2,184,272
2017	669	244,943	$2,517,124
2018	850	246,997	$3,106,826
2019	944	316,812	$3,586,489
2020	790	241,596	$3,240,445
2021	996	294,723	$3,675,343
2022	1,147	395,867	$5,439,757
2023	1,140	364,670	$5,603,764
2024	1,143	280,813	$5,127,179

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	99	710	$778,526
2016	110	714	$1,002,425
2017	115	729	$1,284,649
2018	119	729	$1,506,738
2019	123	695	$1,426,835
2020	140	684	$1,154,940
2021	150	651	$1,328,499
2022	196	908	$2,337,924
2023	191	928	$2,130,268
2024	217	1,175	$3,129,358

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$47,788
2016	N/R	49	$16,509
2017	N/R	13	$11,454
2018	N/R	35	$3,643
2019	N/R	79	$6,786
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	41	$1,698
2023	N/R	17	$48,609
2024	N/R	45	$53,573

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	368	707	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	699	1,578	$65
80053	Blood test, comprehensive group of blood chemicals	513	1,447	$10
36415	Insertion of needle into vein for collection of blood sample	387	607	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	779	3,390	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	41	1,162	$655,080
Jakafi	Ruxolitinib Phosphate	24	720	$411,313
Verzenio	Abemaciclib	18	504	$303,894
Revlimid	Lenalidomide	15	422	$265,185
Imbruvica	Ibrutinib	12	360	$208,822

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	17	$48,695
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	14	$4,615
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	45	$1,109	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amr Z. Hegazi, MD?

Tedicare shows public-source Medicare data for Amr Z. Hegazi, MD (NPI 1366443152), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amr Z. Hegazi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amr Z. Hegazi, MD?

Amr Z. Hegazi, MD is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Amr Z. Hegazi, MD have Open Payments data?

Amr Z. Hegazi, MD has 45 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.